Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.49 |
| ▸ | PGR | P06401 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163146 | 0.86 | NR3C1 (0.53) | NR3C1PGRNR3C2AR | |
| SCHEMBL14144387 | 0.85 | NPC1 (0.39) | NR3C1PGRNPC1LMNARAB9A | |
| SCHEMBL4170029 | 0.82 | RAB9A (0.53) | NR3C1PGRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4173274 | 0.82 | NR3C1 (0.50) | NR3C1PGRNPC1RAB9ANR3C2 | |
| SCHEMBL6692378 | 0.81 | NR3C1 (0.50) | NR3C1PGRNR3C2AR | |
| SCHEMBL4168226 | 0.81 | NR3C1 (0.44) | NR3C1PGRNR3C2AR | |
| SCHEMBL4176611 | 0.81 | NR3C1 (0.51) | NR3C1PGRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4176230 | 0.80 | NR3C1 (0.46) | NR3C1PGRNPC1RAB9ANR3C2 | |
| SCHEMBL4167811 | 0.79 | NR3C1 (0.48) | NR3C1PGRNPC1LMNARAB9A | |
| SCHEMBL4167078 | 0.79 | NR3C1 (0.47) | NR3C1PGRNPC1RAB9ANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | NR3C1 60/4885PGR 5/4885NPC1 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.